Gene polymorphisms in childhood all

Pediatric Blood and Cancer

Volumn 52, Issue 3, 2009, Pages 318-323

  Karathanasis, Nikolaos V ^a   Choumerianou, Despoina M ^a   Kalmanti, Maria ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Acute lymphoblastic leukemia; Children; CYP; MDR1; MTHFR; RFC

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYTOCHROME P450; FOLIC ACID; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; METHOTREXATE; METHYLENETETRAHYDROFOLIC ACID; REDUCED FOLATE CARRIER; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER SUSCEPTIBILITY; CHILDHOOD CANCER; CONSTIPATION; EVENT FREE SURVIVAL; FOLATE METABOLISM; GENE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIVER TOXICITY; MULTIDRUG RESISTANCE GENE 1; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; VOMITING; CHILD; DRUG RESISTANCE; GENETICS; METABOLISM; MULTIDRUG RESISTANCE;

CHILD; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FOLIC ACID; HUMANS; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 58949086522     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21825     Document Type: Review

References (39)

1. Chen CL, Liu Q, Pui CH, et al. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood 1997;89:1701-1707.
2. Sinnett D, Krajinovic M, Labuda D. Genetic susceptibility to childhood acute lymphoblastic leukemia. Leuk Lymphoma 2000; 38:447-462.
3. Pui CH, Relling MV, Downing JR. Mechanisms of disease-Acute lymphoblastic leukemia. N Engl J Med 2004;350:1535-1548.
4. Pui CH, Evans WE. Drug therapy-Treatment of acute lymphoblastic leukemia. N Engl J Med 2006;354:166-178.
5. Rosenblatt DS. Clinically important genes: Methylenetetrahydro- folate reductase. Clin Invest Med 2001;24:56-59.
6. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofo- late reductase. Nat Genet 1995;10:111-113.
7. Blount BC, Mack MM, Wehr CM, et al. Folate deficiency causes uracil misincorporation into human DNA and chromosome breakage: Implications for cancer and neuronal damage. Proc Natl Acad Sci USA 1997;94:3290-3295.
8. Chango A, Emery-Fillon N, de Courcy GP, et al. A polymorphism (80G → A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 2000; 70:310-315.
9. Krajinovic M, Costea I, Chiasson S. Polymorphism of the thymidylate synthase gene and outcome of acute lymphoblastic leukaemia. Lancet 2002;359:1033-1034.
10. Wiemels JL, Smith RN, Taylor GM, et al. Methylenetetrahydro- folate reductase (MTHFR) polymorphisms and riskofmolecularly defined subtypes of childhood acute leukaemia. Proc Natl Acad Sci USA 2001;98:4004-4009.
11. Zanrosso CW, Hatagima A, Emerenciano M, et al. The role of methylenetetrahydrofolate reductase in acute lymphoblastic leukemia in a Brazilian mixed population. Leuk Res 2006;30:477-481.
12. Krajinovic M,Lamothe S, Labuda D, et al. Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lympho-blastic leukaemia. Blood 2004;103:252-257.
13. Oliveira E, Alves S, Quental S, et al. The MTHFR C677T and A1298C polymorphisms and susceptibility to childhood acute lymphoblastic leukemia in Portugal. J Pediatr Hematol Oncol 2005;27:425-429.
14. Schnakenberg E, Mehles A, Cario G, et al. Polymorphisms of methylenetetrahydrofolate reductase (MTHFR) and susceptibility to pediatric acute lymphoblastic leukemia in a German study population. BMC Med Genet 2005;6:23.
15. Petra BG, Janez J, Vita D. Gene-gene interactions in the folate metabolic pathway influence the risk for acute lymphoblastic leukemia in children Leuk Lymphoma 2007;48:786-792.
16. Aplenc R, Thompson J, Han P, et al. Methylenetetrahydro- folate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005;65:2482-2487.
17. de Jonge R, Hooijberg JH, van Zelst BD, et al. Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukaemia. Blood 2005;106:717-720.
18. Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lym-phoma. J Hum Genet 2007;52:166-171.
19. Laverdiere C, Chiasson S, Costea I, et al. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukaemia. Blood 2002;100:3832-3834.
20. Shimasaki N, Mori T, Samejima H, et al. Effects of methylenete- trahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64-68.
21. Ge Y, Haska CL, LaFiura K, et al. Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group. Clin Cancer Res 2007;13:451-457.
22. Lauten M, Asgedom G, Welte K, et al. Thymidylate synthase gene polymorphism and its association with relapse in childhood B-cell precursor acute lymphoblastic leukemia. Haematologica 2003;88: 353-354.
23. Krajinovic M, Costea I, Primeau M, et al. Combining several polymorphisms of thymidylate synthase gene for pharmacogenetic analysis. Pharmacogenomics J 2005;5:374-380.
24. Guengerich FP, Shimada T, Raney KD, et al. Elucidation of catalytic specificities of human cytochrome P450 and glutathione S-transferase enzymes and relevance to molecular epidemiology. Environ Health Perspect 1992;98:75-80.
25. Pakakasama S, Mukda E, Sasanakul W, et al. Polymorphisms of drug-metabolizing enzymes and risk of childhood acute lympho-blastic leukemia. Am J Hematol 2005;79:202-205.
26. Joseph T, Kusumakumary P, Chacko P, et al. Genetic polymorphism of CYP1A1, CYP2D6, GSTM1 and GSTT1 and susceptibility to acute lymphoblastic leukaemia in Indian children. Pediatr Blood Cancer 2004;43:560-567.
27. Canalle R, Burim RV, Tone LG, et al. Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 2004;43:100-109.
28. Lopes LF, Piccoli Fde S, Paixao VA, et al. Association of CYP3A4 genotype with detection of V/Jtrans-rearrangements in the peripheral blood leukocytes of pediatric cancer patients undergoing chemotherapy for ALL. Leuk Res 2004;28:1281-1286.
29. Fojo AT, Ueda K, Slamon DJ, et al. Expression of a multidrug- resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 1987;84:265-269.
30. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33.
31. Plasschaert SL, Groninger E, Boezen M, et al. Influence of functional polymorphisms of the MDR1 gene on vincristine pharmacokinetics in childhood acute lymphoblastic leukaemia. Clin Pharmacol Ther 2004;76:220-229.
32. Jamroziak K, Mlynarski W, BalcerczakE, et al. Functional C3435T polymorphism of MDR1 gene: An impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukaemia. Eur J Haematol 2004;72:314-321.
33. Hattori H, Suminoe A, Wada M, et al. Regulatory polymorphisms of multidrug resistance 1 (MDR1) gene are associated with the development of childhood acute lymphoblastic leukaemia. Leuk Res 2007;31:1633-1640.
34. Siegel D, McGuinness SM, Winski SL, et al. Genotype-phenotype relationship in studies of a polymorphism in NAD(P)H:quinine oxidoreductase 1. Pharmacogenetics 1999;9: 113-121.
35. Lanciotti M, Dufour C, Corral L, et al. Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia 2005;19:214-216.
36. Sirma S, Agaoglu L, Yildiz I, et al. NAD(P)H:quinone oxidor- eductase 1 null genotype is not associated with pediatric de novo acute leukaemia. Pediatr Blood Cancer 2004;43:568-570.
37. Kracht T, Schrappe M, Strehl S, et al. NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. Haemato- logica 2004;89:1492-1497.
38. Carroll WL, Bhojwani D, Min DJ, et al. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer 2006;46:570-578.
39. Pieters R. Genes and proteins mediating drug resistance in acute lymphoblastic leukaemia. Hematol Educ: Education Program Annu Congr Eur Hematol Assoc 2008;2:39-43.